Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update

Canadian Journal of Diabetes

Volumn 39, Issue 4, 2015, Pages 250-252

  Harper, William ^a   Clement, Maureen ^a   Goldenberg, Ronald ^a   Hanna, Amir ^a   Main, Andrea ^a   Retnakaran, Ravi ^a   Sherifali, Diana ^a   Woo, Vincent ^a   Yale, Jean François ^a   Cheng, Alice Y Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ABDOMINAL PAIN; BLADDER CANCER; BODY WEIGHT; CONFUSION; CONGESTIVE HEART FAILURE; DIABETIC KETOACIDOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSURIA; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OSMOTIC DIURESIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; URINARY EXCRETION; URINARY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; CANADA; CONSENSUS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; STANDARDS;

CANADA; CANAGLIFLOZIN; CONSENSUS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HEALTH POLICY; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84938275233     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.05.009     Document Type: Note

References (15)

1. Booth G., Cheng A.Y.Y. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Methods. Can J Diabetes 2013, 37(Supp l1):S4-S7.
2. Health Canada Notice of Compliance Database. Accessed March 6, 2015. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/index-eng.php.
3. Vasilakou D., Karagiannis T., Athanasiadou E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. Ann Intern Med 2013, 159:262-274.
4. Bolinder J., Ljunggren O., Johansson L., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014, 16(2):159-169.
5. Barnett A.H., Orme M.E., Fenici P., et al. Systematic review and network meta-analysis to compare dapagliflozin to other diabetes medications in combination with metformin foradults with type 2 diabetes. Intern Med 2014, S6:S6-006. http://dx.doi.org/10.4172/2165-8048.S6-006.
6. Pacou M., Taieb V., Abrams K.R., et al. Bayesian network meta-analysis to assess relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Value Health 2013, 16:A609.
7. Yang X.P., Lai D., Zhong X.Y., et al. Efficacy and safety of canaglilozin in subjects with type2diabetes: Systematic review and meta-analysis. Eur J Clin Pharmacol 2014, 70:1149-1158.
8. Bode B., Stenlof K., Harris S., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015, 17:294-303.
9. Lin H.W., Tseng C.H. Areview on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol 2014, 2014:719578. doi:10.1155/2014/71958. Epub 2014 Aug 31.
10. U.S. Food and Drug Administration Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too muchacid in the blood. Available from . Accessed 15 May 2015. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery.
11. European Medicines Agency Review Notice. Review of diabetes medicines called SGLT2 inhibitors started. Available from . Accessed 19 June 2015. http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f.
12. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; DOI: . Published online June 15, 2015. http://10.2337/dc15-0843.
13. Health Canada Information Update . Accessed June 22, 2015. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/forxiga-invokana-eng.php.
14. Yale J.F., Bakris G., Cariou B., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014, 16:1016-1027.
15. Harper W., Clement M., Goldenberg R., et al. Canadian Diabetes Association2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Methods. Can J Diabetes 2013, 37(Suppl 1):S61-S68.